Lantheus Inc.

97.00
-1.43 (-1.45%)
At close: Mar 27, 2025, 3:59 PM
96.99
-0.01%
Pre-market: Mar 28, 2025, 04:50 AM EDT

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.

It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody.

The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices.

It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc.

The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Lantheus Inc.
Lantheus  Inc. logo
Country United States
IPO Date Jun 25, 2015
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 808
CEO Brian A. Markison

Contact Details

Address:
331 Treble Cove Road
North Billerica, Massachusetts
United States
Website https://www.lantheus.com

Stock Details

Ticker Symbol LNTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001521036
CUSIP Number 516544103
ISIN Number US5165441032
Employer ID 35-2318913
SIC Code 2835

Key Executives

Name Position
Brian A. Markison Chief Executive Officer & Director
Carol Walker Senior Vice President of Quality
Cheryl Ball Senior Vice President of Strategy & Enterprise Planning
Joann Nestor Senior Vice President of Legal Affairs
Mark Richard Kinarney Senior Director of Investor Relations
Paul M. Blanchfield President

Latest SEC Filings

Date Type Title
Mar 21, 2025 4 Filing
Mar 21, 2025 ARS Filing
Mar 21, 2025 DEFA14A Filing
Mar 21, 2025 DEF 14A Filing
Mar 19, 2025 4 Filing
Mar 17, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing